To our knowledge, this is the first study to directly measure the impact of ATM, p53, DNA-PKcs or RAD51 status on the ability of doxorubicin or cisplatin to stimulate mutations in clonogenically-competent cells, thus modelling events that could lead to therapy-related cancers in vivo. This evidence concerns the gene ATM and cancer.